Techcyte Revenue and Competitors
Estimated Revenue & Valuation
- Techcyte's estimated annual revenue is currently $18.3M per year.
- Techcyte's estimated revenue per employee is $145,000
- Techcyte's total funding is $35M.
Employee Data
- Techcyte has 126 Employees.
- Techcyte grew their employee count by 26% last year.
Techcyte's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | VP User Experience | Reveal Email/Phone |
3 | VP Platform | Reveal Email/Phone |
4 | VP Product Management | Reveal Email/Phone |
5 | VP Regulatory Affairs | Reveal Email/Phone |
6 | Head Developer | Reveal Email/Phone |
7 | Chief Financial Officer | Reveal Email/Phone |
8 | Director Support | Reveal Email/Phone |
9 | Chief Strategy Officer (CSO) | Reveal Email/Phone |
10 | Senior Director Veterinary Strategy | Reveal Email/Phone |
Techcyte Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $176250M | 236276 | -1% | $1M | $2.3T |
What Is Techcyte?
Accelerating diagnosis through digital microscopy and machine learning. Techcyte is cloud-based digital microscopy software that uses machine learning to provide pre-analysis for final review by a Doctor, technician or other qualified individual. Our technology identifies and classifies cell types and visible organisms in peripheral blood, aspirate bone, urine, fecal, and pap smears.
keywords:N/A
$35M
Total Funding
126
Number of Employees
$18.3M
Revenue (est)
26%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Techcyte News
Techcyte has collaborated with Zoetisthe world's leading animal health companysince 2019 to develop the core Vetscan Imagyst technology.
As the technology engine behind the multi-use AI-driven platform, Vetscan Imagyst, Techcyte is proud to announce the addition of artificial...
Other Companies in Orem
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $33.3M | 133 | -1% | N/A |
#2 | N/A | 135 | 9% | N/A |
#3 | $42.5M | 143 | 11% | N/A |
#4 | $33.5M | 145 | 23% | N/A |
#5 | $23.3M | 146 | N/A | N/A |